Display options
Cite
Mao Y, Feng Q, Zheng P, et al. Low tumor purity is associated with poor prognosis, heavy mutation burden, and intense immune phenotype in colon cancer. Cancer Manag Res. 2018;10:3569-3577doi: 10.2147/CMAR.S171855.
Mao, Y., Feng, Q., Zheng, P., Yang, L., Liu, T., Xu, Y., Zhu, D., Chang, W., Ji, M., Ren, L., Wei, Y., He, G., & Xu, J. (2018). Low tumor purity is associated with poor prognosis, heavy mutation burden, and intense immune phenotype in colon cancer. Cancer management and research, 103569-3577. https://doi.org/10.2147/CMAR.S171855
Mao, Yihao, et al. "Low tumor purity is associated with poor prognosis, heavy mutation burden, and intense immune phenotype in colon cancer." Cancer management and research vol. 10 (2018): 3569-3577. doi: https://doi.org/10.2147/CMAR.S171855
Mao Y, Feng Q, Zheng P, Yang L, Liu T, Xu Y, Zhu D, Chang W, Ji M, Ren L, Wei Y, He G, Xu J. Low tumor purity is associated with poor prognosis, heavy mutation burden, and intense immune phenotype in colon cancer. Cancer Manag Res. 2018 Sep 17;10:3569-3577. doi: 10.2147/CMAR.S171855. eCollection 2018. PMID: 30271205; PMCID: PMC6149864.
Copy Download .nbib Format: NLM
Share it on

Cancer Manag Res. 2018 Sep 17;10:3569-3577. doi: 10.2147/CMAR.S171855. eCollection 2018.

Low tumor purity is associated with poor prognosis, heavy mutation burden, and intense immune phenotype in colon cancer.

Cancer management and research

Yihao Mao, Qingyang Feng, Peng Zheng, Liangliang Yang, Tianyu Liu, Yuqiu Xu, Dexiang Zhu, Wenju Chang, Meiling Ji, Li Ren, Ye Wei, Guodong He, Jianmin Xu

Affiliations

  1. Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai 200030, China, [email protected], [email protected].
  2. Shanghai Engineering Research Center of Colorectal Cancer Minimally Invasive, Shanghai 200030, China, [email protected], [email protected].

PMID: 30271205 PMCID: PMC6149864 DOI: 10.2147/CMAR.S171855

Abstract

PURPOSE: Tumor purity is defined as the proportion of cancer cells in the tumor tissue. The impact of tumor purity on colon cancer (CC) prognosis, genetic profile, and microenvironment has not been thoroughly accessed.

MATERIALS AND METHODS: Clinical and transcriptomic data from three public datasets, GSE17536/17537, GSE39582, and TCGA, were retrospectively collected (n=1,248). Tumor purity of each sample was inferred by a computational method based on transcriptomic data. Survival-related analyses were performed on microarray dataset containing GSE17536/17537 and GSE39582 (n=794), whereas TCGA dataset was utilized for subsequent genomic analysis (n=454).

RESULTS: Right-sided CC patients showed a significantly lower tumor purity. Low purity CC conferred worse survival, and tumor purity was identified as an independent prognostic factor. Moreover, high tumor purity CC patients benefited more from adjuvant chemotherapy. Subsequent genomic analysis found that the mutation burden was negatively associated with tumor purity, with only

CONCLUSION: Tumor purity exhibited potential value for CC prognostic stratification as well as adjuvant chemotherapy benefit prediction. The relative worse survival in low purity CC may attribute to higher mutation frequency in key pathways and purity-related microenvironmental changing.

Keywords: adjuvant chemotherapy; colon cancer; prognosis; tumor microenvironment; tumor purity

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

References

  1. Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 - PubMed
  2. Nat Med. 2013 Nov;19(11):1423-37 - PubMed
  3. Ann Oncol. 2014 Mar;25(3):644-51 - PubMed
  4. Sci Transl Med. 2016 Mar 2;8(328):328rv4 - PubMed
  5. Cancer Cell. 2016 Apr 11;29(4):587-601 - PubMed
  6. Bioinformatics. 2010 Jan 1;26(1):139-40 - PubMed
  7. CA Cancer J Clin. 2018 Jan;68(1):7-30 - PubMed
  8. J Natl Compr Canc Netw. 2017 Mar;15(3):411-419 - PubMed
  9. Clin Cancer Res. 2017 Oct 15;23(20):6279-6291 - PubMed
  10. Gastroenterology. 2012 Mar;142(3):562-571.e2 - PubMed
  11. Cell Oncol. 2007;29(5):387-98 - PubMed
  12. Bioinformatics. 2014 Aug 1;30(15):2121-9 - PubMed
  13. Nat Commun. 2013;4:2612 - PubMed
  14. Br J Cancer. 2017 Jul 25;117(3):421-431 - PubMed
  15. PLoS One. 2012;7(1):e30806 - PubMed
  16. J Cell Biol. 2012 Feb 20;196(4):395-406 - PubMed
  17. Nature. 2013 Sep 19;501(7467):346-54 - PubMed
  18. Crit Rev Oncol Hematol. 2015 Apr;94(1):18-30 - PubMed
  19. Immunity. 2014 Jul 17;41(1):49-61 - PubMed
  20. Nature. 2012 Jul 18;487(7407):330-7 - PubMed
  21. Clin Cancer Res. 2004 Nov 1;10(21):7252-9 - PubMed
  22. Nucleic Acids Res. 2009 Jan;37(1):1-13 - PubMed
  23. Gastroenterology. 2010 Mar;138(3):958-68 - PubMed
  24. PLoS Med. 2013;10(5):e1001453 - PubMed
  25. Ann Oncol. 2018 Mar 1;29(3):616-623 - PubMed
  26. Cell. 2011 Mar 4;144(5):646-74 - PubMed
  27. Nat Genet. 2003 Jul;34(3):267-73 - PubMed
  28. Br J Cancer. 2010 May 11;102(10):1519-23 - PubMed
  29. Genome Biol. 2011;12(4):R41 - PubMed
  30. Carcinogenesis. 2018 Feb 9;39(2):272-282 - PubMed
  31. PLoS One. 2013 May 29;8(5):e64814 - PubMed
  32. Drugs. 2018 Jun;78(8):789-798 - PubMed
  33. Nat Commun. 2015 Dec 04;6:8971 - PubMed
  34. Nature. 2012 Mar 28;483(7391):603-7 - PubMed
  35. Trends Immunol. 2015 Apr;36(4):229-39 - PubMed
  36. Nat Biotechnol. 2012 May;30(5):413-21 - PubMed
  37. Nat Protoc. 2009;4(1):44-57 - PubMed
  38. Cancer Immunol Res. 2018 Jan;6(1):87-97 - PubMed
  39. Int J Cancer. 2016 Jul 15;139(2):446-56 - PubMed
  40. Cancer Lett. 2017 Feb 28;387:61-68 - PubMed
  41. Cancer Res. 2006 Feb 15;66(4):2129-37 - PubMed
  42. Genome Biol. 2014 Aug 07;15(8):419 - PubMed
  43. Oncogene. 2008 Sep 18;27(41):5497-510 - PubMed
  44. Ann Oncol. 2013 Jan;24(1):179-85 - PubMed

Publication Types